This study pooled data from six randomized controlled trials to compare itraconazole
and fluconazole in the per os treatment of acute vaginal and vulvovaginal candidiasis.
The authors sought to compare itraconazole and fluconazole with respect to the in
vivo and in vitro efficacy and safety of each drug. The six studies in the meta-analysis
included 1092 enrolled non-pregnant patients with microscopically or microbiologically
culture confirmed vaginal/vulvovaginal candidiasis. The results of the meta-analysis
showed no difference between the two drugs in every comparison studied, including
clinical cure and improvement at both the first follow-up visit (pooled odds ratio
[OR] 0.94, 95% confidence interval [CI] 0.6–1.48) and second follow-up visit (OR 1.09,
95% CI 0.68–1.75), mycologic cure at the first and second follow-ups (OR 0.73, 95%
CI 0.31–1.7 and OR 0.71, 95% CI 0.49–1.03, respectively), withdrawal of patients secondary
to severe adverse events, and adverse events affecting the nervous and digestive systems.
The authors concluded that both fluconazole and itraconazole can be used for efficacious
and safe treatment of uncomplicated vaginal/vulvovaginal candidiasis.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Emergency MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2008 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
